Authors as published in PMC11320741 (Hungarian mEHT research group), 2024: Triple-negative breast cancer mouse study that states the mouse-to-human conversion explicitly: 7.5 mg/kg in mice equals 0.6 mg/kg in humans, and notes 1 mg/kg daily was safe in AML patients.
In our mouse model, the synergism between mEHT and IVM was achieved at a 7.5 mg/kg dose of IVM. This dose is equivalent to a 0.6 mg/kg dose in humans.
Authors as published in PMC11320741 (Hungarian mEHT research group), 2024: Triple-negative breast cancer mouse study that states the mouse-to-human conversion explicitly: 7.5 mg/kg in mice equals 0.6 mg/kg in humans, and notes 1 mg/kg daily was safe in AML patients. C5 'within human safe limits' question. Study type: mouse TNBC model (4T1-type) plus cell work. Dose: ivermectin 7.5 mg/kg daily intraperitoneal, alone and with modulated electro-hyperthermia; product from MedChemExpress (#HY-15310); comparator vehicle. The paper applies the body-surface-area conversion (same method as the FDA guidance, IVA-19) and states 7.5 mg/kg mouse = 0.6 mg/kg human, that 0.6 mg/kg is well tolerated clinically, that neurotoxicity has been seen in healthy adults at doses up to 2 mg/kg, and that 1 mg/kg daily was safe in AML patients. NOTE: author list, journal name and volume are as printed on the PMC record; the PMC record itself must be opened for the exact author string before this row is cited for authorship. Funding/conflicts not transcribed here – not captured. Key arithmetic: the book's 10 mg/kg mouse dose is about 0.81 mg/kg HED, i.e. four times the approved 0.2 mg/kg, so 'within human safe limits' is true only in the sense that 0.6-2 mg/kg has been given in trials, not that it is the approved dose. Study type: animal.
